BIIB Articles, Biogen Inc. - From 10/19/23

Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer's disease Additional late-...

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 3.66% on an annualized basis producing an average annual return of 11.04...

In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehe...

The U.S. Centers for Medicare and Medicaid Services has revised its policy permitting multiple uses of amyloid positron emission tomograp...

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic too...

Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisa...

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 3.54% on an annualized basis producing an average annual return of 10.81...

Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA appr...

Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (...

California Attorney General Rob Bonta has taken legal action against two anti-abortion organizations, Heartbeat International (HBI)&...